MLYSMineralys Therapeutics, Inc.

Nasdaq mineralystx.com


$ 14.92 $ 0.28 (1.91 %)    

Thursday, 09-May-2024 11:07:35 EDT
QQQ $ 441.20 $ 0.74 (0.17 %)
DIA $ 392.61 $ 2.50 (0.64 %)
SPY $ 519.32 $ 1.88 (0.36 %)
TLT $ 90.18 $ 0.12 (0.13 %)
GLD $ 216.25 $ 1.55 (0.72 %)
$ 14.65
$ 14.64
$ 0.00 x 0
$ 0.00 x 0
$ 14.09 - $ 14.94
$ 5.85 - $ 17.70
277,799
na
175.8M
$ 2.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-15-2023 12-31-2022 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mineralys-therapeutics-q1-2024-gaap-eps-070-misses-067-estimate

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate...

 goldman-sachs-initiates-coverage-on-mineralys-therapeutics-with-buy-rating-announces-price-target-of-30

Goldman Sachs analyst Richard Law initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces...

 mineralys-therapeutics-q4-eps-061-beats-082-estimate

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate o...

 earnings-scheduled-for-march-21-2024

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per s...

 why-compass-minerals-international-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results.

 arm-holdings-posts-upbeat-results-joins-hershey-cyberark-software-wynn-resorts-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks traded mixed, with the Dow Jones gaining around 20 points on Thursday.

 why-aar-shares-are-trading-lower-by-7-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.

 mineralys-therapeutics-further-defines-endotype-specific-targeted-approach-to-treatment-of-uncontrolled-or-resistant-hypertension-with-lorundrostat-data-at-aha-scientific-sessions-2023

– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feed...

 mineralys-therapeutics-q3-eps-057-beats-076-estimate

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate o...

 earnings-scheduled-for-november-7-2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.

 mineralys-therapeutics-presents-new-post-hoc-analysis-from-target-htn-phase-2-trial-of-lorundrostat-in-late-breaking-poster-session-at-asn-kidney-week-2023-meeting

– Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorun...

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 647 companies set new 52-week lows.

 5m-bet-on-treehouse-foods-check-out-these-3-stocks-insiders-are-buying

Although U.S. stocks closed higher on Friday, there were a few notable insider trades.

 mineralys-therapeutics-announced--target-htn-successfully-met-its-primary-endpoint-key-secondary-endpoint-results-demonstrated-a-change-in-diastolic-aobp-of--71-mmhg-with-50mg

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to targe...

 mineralys-therapeutics-announced-jama-publication-of-full-target-htn-phase-2-trial-results-for-lorundrostat-in-uncontrolled-and-treatment-resistant-hypertension

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to targe...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION